Table 1 "Patients-to-be-treated " by type of treatment, based on proportion of patients with a contraindication and intolerance (n = 286)
From: Assessing the impact of heart failure specialist services on patient populations
| Â | Proportion with contra-indication (Pci) | Prop. intolerant (Pint) | Proportion eligible Pe = 1 - (Pci + Pint) | Proportion already treated (Pt) | Pe-u (= Pe - Pt) | Incremental number of "patients-to-be-treated" (= n * Pe-u) |
|---|---|---|---|---|---|---|
Spironolactone | 0.08* (95% CI 0.04–0.15) | 0.08 [10] (95% CI 0.06–0.1) | 0.84 | 0.25* (95% CI 0.18–0.34) | 0.59 | 169 |
b-blockers | 0.2* (95% CI 0.13–0.28) | 0.052 [29] (95% CI 3.9–6.5) | 0.748 | 0.12* (95% CI 0.07–0.19) | 0.628 | 180 |
N-LEI | 0* | 0.15** | 0.85 | 0 | 0.85 | 243 |